Stock Upgrades Today See Wall Street Boost Confidence

 TopRated
 
  TopRated
 
Follow  Message
 
 
 
TopRatedStocks uncovering top-rated companies. Providing quick insights and recommendations, they help investors discover high-potential stocks based on robust metrics.
 

•  20 Nov 2025
 

•   ACM  
   
  0.00%
•   AEO  
   
  0.00%
•   AFRM  
   
  0.00%
•   ALB  
   
  0.00%
•   AMAL  
   
  0.00%

$ACM saw multiple reaffirmations today as Citigroup, UBS, and Baird maintained Buy and Outperform recommendations. Analysts highlight a potential upside of 29.17%, signaling strong confidence in AECOM ongoing projects and long-term growth. With consistent support from major institutions, ACM continues to be a stock worth watching for traders seeking steady upside.

$AEO maintains a Buy rating from UBS, though analysts point to a slight downside of 4.48%. While not the strongest upside case, it remains a solid play for investors favoring established retail names, with market positioning and brand loyalty supporting stability.

$AFRM retains a Buy recommendation from Truist Securities, with an impressive 48.10% upside projected. Affirm strong position in the payments sector and ongoing expansion into consumer finance make it a high-potential pick for traders seeking growth opportunities.

$ALB is held at Outperform by BMO Capital, though analysts forecast a 17.66% downside. Despite this, Albemarle position in specialty chemicals provides a defensive edge for those looking to balance riskier trades in a volatile market.

$AMAL received an upgrade from Piper Sandler, moving from Underweight to Neutral with a 15.87% upside. This signals growing confidence in Amalgamated Financial stability and potential for moderate gains over the near term.

$APLD continues to attract attention with a Buy rating from Northland Securities, reflecting optimism in its AI and data center initiatives. The $1.5B AI factory project underlines a long-term growth story in the tech infrastructure space.

$APO was raised to Overweight by Morgan Stanley, signaling expectations for a growth reacceleration. Investors can watch for potential momentum as Apollo Global Capital positions itself in the market.

$APPF retains a Buy rating from DA Davidson, with a 43.94% projected upside. AppFolio strength in property management software and SaaS solutions continues to drive solid growth potential.

$APTV keeps an Outperform recommendation from RBC Capital, with upside of 34.38%. Aptiv focus on automotive technology and connected solutions positions it well for traders targeting innovative sectors.

$ARMK maintains a Buy rating from Citigroup, with a 26.48% upside. Aramark stable service offerings and steady earnings growth make it a reliable option for medium-term traders.

$ARWR retains Outperform and Buy ratings from RBC Capital and Chardan Capital, showing a 29.66% upside. Arrowhead Pharmaceuticals continues to benefit from strong biotech pipelines, offering attractive speculative potential.

$AS remains a Buy and Outperform pick with a 28.79% upside, supported by UBS and Evercore ISI Group. Amer Sports’ global presence and diverse product line support moderate growth potential for investors.

$AU focus on expanding production at the Geita mine shows commitment to growth, potentially lifting output and long-term profitability.

$BAC maintains an Outperform from Oppenheimer, projecting an 11.75% upside. Bank of America robust financial positioning offers stability in a fluctuating market environment.

$BIDU continues to enjoy multiple Buy ratings, with upside projections ranging from 24.11% to 46.47%. Baidu leadership in AI, cloud computing, and search technology makes it a standout growth stock for tech-focused traders.

$BITF remains a Buy, though analysts highlight near-term margin pressures. The pivot toward AI and HPC-driven data centers could unlock upside by 2027, making it a speculative but intriguing pick.

$BLSH was upgraded to Buy by Deutsche Bank, with a notable 70% upside. This upgrade highlights strong potential in the stock and significant near-term upside for traders.

$BMA received initial Buy coverage from UBS, though analysts note a 29.02% downside. Caution is advised, though the stock may present selective opportunities for value-oriented traders.

$C maintains an Outperform from Oppenheimer, projecting a 15.97% upside. Citigroup steady banking operations continue to appeal to conservative traders seeking moderate growth.

$CURB was upgraded from Neutral to Buy by Citigroup, signaling 15.21% potential upside. Investors may find Curbline Properties appealing for its improving outlook in real estate.

$DT maintains a Buy from Truist Securities with a 38.61% upside. Dynatrace software performance monitoring solutions provide strong growth tailwinds.

$FCX was upgraded to Sector Outperform by Scotiabank and maintains Outperform from BMO Capital, with an 18.33% upside. Freeport-McMoRan recovery efforts post-incident at its Grasberg mine support this bullish case.

$FTAIM maintains a Buy from BTIG, projecting 39.89% upside. The aviation preferred stock offers traders exposure to the growing aerospace financing sector.

$HD keeps its Buy and Outperform ratings with 30.68% upside. Home Depot continues to benefit from strong housing demand and retail resilience.

$IHS maintains a Buy rating from Tigress Financial, projecting 51.59% upside. IHS Holding’s infrastructure and energy focus continues to offer attractive opportunities for growth-oriented traders.

$IMTX keeps an Outperform rating with an impressive 66.87% upside. Immatics N.V. offers compelling potential in the biotech sector, particularly for traders seeking high-reward opportunities.

$INOD holds a Buy from BWS Financial, with a 26% projected revenue increase. Innodata strong performance in AI and data processing positions it as a key stock for technology-focused portfolios.

$JHX retains Outperform with a 39.08% upside, supported by Baird and Oppenheimer. James Hardie Industries’ construction materials remain in demand, making it a solid growth play.

$KNTK maintains Outperform with a 53.59% upside, highlighting strong speculative potential in Kinetik Holdings.

$LFMD retains a Buy rating from HC Wainwright, projecting a massive 229.14% upside. LifeMD growth story makes it a high-risk, high-reward play for aggressive traders.

$NVDA continues to attract attention with high growth expectations, potentially rallying around 72%. The company remains central to AI and gaming innovations.

$VREX maintains Buy and Outperform with a 77.30% upside, positioning it as a standout growth stock in medical imaging.

View All Headlines